Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept in Cpc-PH due to HFpEF
2023-509141-12-00Phase 2Completed
- Sponsor
- Acceleron Pharma Inc.
- Start
- Sep 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension (PH) and heart failure with preserved ejection fraction (HFpEF) comparing Sotatercept with Placebo (2 arms). Primary endpoint: Change from baseline in pulmonary vascular resistance at Week 24. Started Sep 2024; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary hypertension (PH)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2023-509141-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509141-12-00.